A 52-year-old non-obese man with a four-year history of type 2 diabetes mellitus developed unexpected glycemic deterioration during chronic dipeptidyl peptidase-4 inhibitor therapy despite exhibiting preserved endogenous pancreatic beta-cell function, according to a detailed clinical case report published in Cardiovascular Diabetology – Endocrinology Reports. The case report, documented by Dr. Sai Prasad and colleagues, highlights an unusual pattern of secondary therapeutic failure following almost two years of stable glycemic control on combined metformin and sitagliptin. While progressive loss of glycemic control during second-line diabetes management is conventionally assumed to stem from progressive beta-cell decline, comprehensive laboratory evaluations in this patient revealed normal insulin and C-peptide concentrations, leading the investigators to propose acquired incretin resistance as an under-recognised alternative pathophysiological mechanism underlying dipeptidyl peptidase-4 inhibitor treatment failure.
Type 2 diabetes mellitus is a chronic progressive metabolic disorder defined by insulin resistance and gradual beta-cell failure that affects more than 537 million adults across the globe. Disease management traditionally follows a stepwise therapeutic escalation, initiating pharmacological escalation when lifestyle interventions and first-line metformin monotherapy no longer achieve individualised glycemic targets. Among recommended second-line antidiabetic drug classes, dipeptidyl peptidase-4 inhibitors—such as sitagliptin, vildagliptin, saxagliptin, and linagliptin—have achieved extensive clinical adoption due to their favourable safety profile, neutral impact on body weight, and minimal risk of provoking hypoglycemia. These pharmacological agents operate by impeding the enzymatic degradation of endogenous incretin peptides, predominantly glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thereby augmenting glucose-dependent insulin release from pancreatic beta-cells and simultaneously attenuating inappropriate glucagon secretion from alpha-cells.
Pivotal clinical trials have shown that adding a dipeptidyl peptidase-4 inhibitor to existing metformin regimens typically lowers glycated haemoglobin by 0.5% to 1.0%, maintaining therapeutic efficacy across two-year follow-up intervals. Nevertheless, secondary treatment failure remains an established clinical reality across every class of antidiabetic medication over prolonged periods. Landmark clinical investigations, including the United Kingdom Prospective Diabetes Study and A Diabetes Outcome Progression Trial, demonstrated that progressive beta-cell dysfunction necessitates treatment intensification in approximately half of all diagnosed patients within three years of initial management. In those long-term trials, worsening glycemic indices consistently tracked declining beta-cell secretory capacity, evidenced by diminished homeostatic model assessment of beta-cell function values and falling circulating C-peptide concentrations. However, emerging preclinical and clinical observations indicate that alternative cellular mechanisms may specifically drive treatment failure in patients receiving incretin-targeted therapies.
In the published report, the 52-year-old patient originally established satisfactory glycemic control on metformin monotherapy administered at 1000 mg twice daily following his initial diagnosis four years earlier. After his glycated haemoglobin subsequently rose to 7.6%, the managing physician escalated therapy by adding the dipeptidyl peptidase-4 inhibitor sitagliptin at a dosage of 100 mg once daily approximately 30 months prior to the reported evaluation. The clinician selected a dipeptidyl peptidase-4 inhibitor rather than an injectable glucagon-like peptide-1 receptor agonist based on practical clinical judgment, accommodating the patient’s strong preference for oral medication, the moderate extent of glycemic elevation at that juncture, and significant economic considerations within the Indian healthcare setting, where glucagon-like peptide-1 receptor agonists remain substantially more costly and less accessible than oral incretin enhancers.
Following the initiation of dual therapy with metformin and sitagliptin, the patient experienced approximately 22 months of reliable glycemic stability, during which his glycated haemoglobin remained between 6.5% and 6.8% and routine self-monitored blood glucose diaries showed stable readings. Despite maintaining strict adherence to his prescribed medication regimen, he subsequently developed progressive and unexplained hyperglycemia over an eight-month span, during which his glycated haemoglobin increased substantially from 6.7% to 8.4%. Corresponding biochemical assessments documented fasting plasma glucose elevations to 168 mg/dL and two-hour postprandial glucose surges to 248 mg/dL. Detailed clinical verification confirmed that therapeutic adherence had remained continuous throughout this period, corroborated by independent pharmacy refill logs, returned pill counts, and direct patient reporting that confirmed no doses had been omitted.
The evaluating clinical team conducted an exhaustive diagnostic assessment to rule out confounding secondary causes of worsening blood glucose levels before drawing mechanistic conclusions. The patient reported no dietary indiscretion, recent fluctuations in weight, acute intercurrent illnesses, emotional stress, or exposure to medications known to impair carbohydrate metabolism, such as corticosteroids or sympathomimetic agents. Furthermore, his clinical background was negative for episodes of acute or chronic pancreatitis, alcohol consumption, and autoimmune disorders, while his total body weight remained completely unchanged at 72 kg throughout the eight months of glycemic deterioration. Physical anthropometry revealed a height of 170 cm, a body mass index of 24.9 kg/m², a normal blood pressure of 128/82 mmHg, and a waist circumference of 88 cm, remaining below the Asian-specific threshold of 90 cm established for abdominal obesity.
Extensive biochemical testing demonstrated that the patient’s endogenous pancreatic beta-cell secretory function remained preserved despite persistent marked hyperglycemia. Laboratory testing showed a normal fasting plasma insulin level of 14 µIU/mL, a fasting C-peptide concentration of 2.1 ng/mL, and a calculated homeostatic model assessment of beta-cell function of 68%, accompanied by mild baseline insulin resistance reflected by a homeostatic model assessment of insulin resistance score of 2.3. Circulating autoimmune markers were uniformly negative, including glutamic acid decarboxylase-65 autoantibodies, insulinoma-associated antigen-2 autoantibodies, and insulin autoantibodies. Additional systemic assessments showed normal thyroid-stimulating hormone at 2.1 mIU/L, morning cortisol at 12.4 µg/dL, hepatic transaminases with aspartate aminotransferase at 28 U/L and alanine aminotransferase at 32 U/L, and preserved renal function with serum creatinine at 88 µmol/L and an estimated glomerular filtration rate of 92 mL/min/1.73 m².
Faced with deteriorating glycemic parameters alongside preserved endogenous insulin secretion, clinicians discontinued sitagliptin while continuing metformin at 1000 mg twice daily, opting to initiate low-dose basal insulin glargine at 10 units administered subcutaneously at bedtime with titration guided by fasting glucose. The decision to select basal insulin rather than switching to an alternative incretin-directed drug, such as a glucagon-like peptide-1 receptor agonist, was made specifically to evaluate the hypothesis of incretin-pathway resistance, as choosing another drug operating through the same hormonal receptor cascade would not have delivered equivalent diagnostic clarity. The patient maintained his baseline diet and activity without modification. Within six weeks of starting basal insulin, fasting plasma glucose improved to 118 mg/dL and postprandial glucose dropped to 162 mg/dL without adverse hypoglycemic events. By three months, glycated haemoglobin declined to 7.1% with preserved C-peptide at 2.3 ng/mL, ultimately stabilising at 6.9% after six months on 12 units of glargine with stable body weight at 73 kg.
To contextualise the clinical observations, the authors reviewed preclinical molecular research detailing how prolonged incretin stimulation can trigger cellular desensitisation of glucagon-like peptide-1 receptors. Preclinical investigations have established that following agonist binding, glucagon-like peptide-1 receptors undergo rapid internalisation through clathrin-mediated endocytic pathways, after which internalized receptors are directed either toward membrane recycling or lysosomal degradation. Continuous ligand exposure progressively shifts this intracellular balance toward degradative pathways, inducing an overall reduction in surface receptor expression. In parallel, chronic receptor activation induces phosphorylation of intracellular receptor domains by G-protein receptor kinases, which promotes the recruitment of beta-arrestin and causes functional uncoupling of the receptor from downstream intracellular G-protein signaling cascades, thereby attenuating cellular insulinotropic responsiveness to incretin stimulation.
Supporting experimental evidence for incretin receptor desensitisation has accumulated largely within rodent and cell culture experimental models. Laboratory studies utilizing isolated rat pancreatic islets have demonstrated that continuous exposure to supraphysiological concentrations of glucagon-like peptide-1 leads to progressive suppression of insulin secretory responses across 24 to 48 hours of observation. Similarly, chronic administration of glucagon-like peptide-1 receptor agonists in diabetic mouse models produced measurable declines in glucose-lowering efficacy over time, coinciding with marked reductions in pancreatic receptor density. The authors cautioned, however, that directly translating these animal findings to human dipeptidyl peptidase-4 inhibitor therapy involves critical caveats, because dipeptidyl peptidase-4 inhibitors elicit only modest two- to three-fold elevations in endogenous incretin concentrations, contrasting sharply with the supraphysiological concentrations utilized in animal models or produced by therapeutic receptor agonists.
The patient’s non-obese phenotype represents another critical element when interpreting the clinical course, as dipeptidyl peptidase-4 inhibitors generally produce greater glycemic improvements in lean and Asian individuals whose disease phenotype typically features predominant beta-cell dysfunction rather than severe insulin resistance. The authors also addressed the peer-review inquiry of why a glucagon-like peptide-1 receptor agonist was not substituted to challenge the incretin pathway directly at pharmacological hormone concentrations. They explained that receptor agonists produce circulating concentrations five to ten times greater than dipeptidyl peptidase-4 inhibitors, meaning an observed glycemic recovery might simply reflect supraphysiological agonism overcoming partial receptor desensitisation, whereas treatment failure would fail to distinguish between acquired desensitisation and primary pathway defects; furthermore, clinical prioritization demanded rapid, predictable glycemic restoration in a patient with a glycated haemoglobin of 8.4%.
The authors explicitly outlined several important limitations of their report, emphasising that an isolated clinical case observation cannot establish disease causality, define population prevalence, or confirm a definitive novel diagnostic entity. Beta-cell secretory capacity was assessed using fasting biochemical indices rather than dynamic mixed-meal tolerance tests or oral glucose tolerance tests, which would have offered a more thorough evaluation of postprandial secretory reserve and dynamic incretin physiology. Furthermore, circulating concentrations of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide were not measured due to clinical resource limitations, direct assessment of pancreatic receptor expression was technically infeasible, sitagliptin re-challenge was not attempted for ethical reasons following clinical recovery, and subtle unmeasured lifestyle variations could not be completely excluded. Nevertheless, the investigators concluded that secondary treatment failure on dipeptidyl peptidase-4 inhibitors should prompt clinicians to verify beta-cell function before assuming beta-cell exhaustion, considering alternative drug classes when endogenous insulin secretion remains intact.
Subject of Research: Secondary treatment failure and potential acquired incretin resistance during chronic dipeptidyl peptidase-4 inhibitor therapy in type 2 diabetes
Article Title: Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance
Article References: Prasad, S., Ahuja, A., Sharma, S., Nagda, J., Agrawal, S., Parmar, V., & Vardhan, H. (2026). Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance. Cardiovascular Diabetology – Endocrinology Reports, 12(1), Article 24. https://doi.org/10.1186/s40842-026-00296-2
Image Credits: AI Generated
DOI: 10.1186/s40842-026-00296-2
Keywords: dipeptidyl peptidase-4 inhibitors, sitagliptin, type 2 diabetes mellitus, incretin resistance, beta-cell function, glycemic control, secondary treatment failure, glucagon-like peptide-1, insulin glargine, C-peptide, HOMA-beta, metformin, GLP-1 receptor desensitisation, fasting plasma glucose, glycated haemoglobin, case report, insulin resistance, endogenous insulin secretion
News Source: Ophelia Keating. (November 12, 2026). Preserved Beta-Cell Function Points to Acquired Incretin Resistance in Case Report. Scienmag.



